Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
30
MYNZ Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-2.03%
Day range:
$1.09 - $1.28
52-week range:
$0.92 - $8.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.52x
P/B ratio:
1.87x
Volume:
355.3K
Avg. volume:
702.8K
1-year change:
-83.23%
Market cap:
$6.1M
Revenue:
$894K
EPS (TTM):
-$57.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MYNZ
Mainz Biomed NV
|
$300K | -$2.80 | 39.69% | -62.5% | $14.00 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MYNZ
Mainz Biomed NV
|
$1.12 | $14.00 | $6.1M | -- | $0.00 | 0% | 0.52x |
|
BNTX
BioNTech SE
|
$94.16 | $138.33 | $22.6B | 191.55x | $0.00 | 0% | 6.41x |
|
CVAC
CureVac NV
|
$4.21 | $5.31 | $948M | 5.89x | $0.00 | 0% | 11.69x |
|
EVO
Evotec SE
|
$3.1400 | $5.4436 | $1.1B | -- | $0.00 | 0% | 1.34x |
|
IFRX
InflaRx NV
|
$1.08 | $11.24 | $73.2M | -- | $0.00 | 0% | 333.70x |
|
IMTX
Immatics NV
|
$10.22 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 13.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MYNZ
Mainz Biomed NV
|
249.65% | 1.858 | 67.29% | 0.13x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MYNZ
Mainz Biomed NV
|
-- | -- | -607.71% | -2631.22% | -- | -- |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Mainz Biomed NV vs. Competitors
-
Which has Higher Returns MYNZ or BNTX?
BioNTech SE has a net margin of -- compared to Mainz Biomed NV's net margin of -1.89%. Mainz Biomed NV's return on equity of -2631.22% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital MYNZMainz Biomed NV-- -- $2.8M BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About MYNZ or BNTX?
Mainz Biomed NV has a consensus price target of $14.00, signalling upside risk potential of 1150%. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 50.08%. Given that Mainz Biomed NV has higher upside potential than BioNTech SE, analysts believe Mainz Biomed NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings MYNZMainz Biomed NV0 0 0 BNTXBioNTech SE14 5 0 -
Is MYNZ or BNTX More Risky?
Mainz Biomed NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock MYNZ or BNTX?
Mainz Biomed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mainz Biomed NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MYNZ or BNTX?
Mainz Biomed NV quarterly revenues are --, which are smaller than BioNTech SE quarterly revenues of $1.8B. Mainz Biomed NV's net income of -- is lower than BioNTech SE's net income of -$33.5M. Notably, Mainz Biomed NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mainz Biomed NV is 0.52x versus 6.41x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MYNZMainz Biomed NV0.52x -- -- -- BNTXBioNTech SE6.41x 191.55x $1.8B -$33.5M
-
Which has Higher Returns MYNZ or CVAC?
CureVac NV has a net margin of -- compared to Mainz Biomed NV's net margin of -5832.47%. Mainz Biomed NV's return on equity of -2631.22% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital MYNZMainz Biomed NV-- -- $2.8M CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About MYNZ or CVAC?
Mainz Biomed NV has a consensus price target of $14.00, signalling upside risk potential of 1150%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 26.44%. Given that Mainz Biomed NV has higher upside potential than CureVac NV, analysts believe Mainz Biomed NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings MYNZMainz Biomed NV0 0 0 CVACCureVac NV1 3 0 -
Is MYNZ or CVAC More Risky?
Mainz Biomed NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock MYNZ or CVAC?
Mainz Biomed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mainz Biomed NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MYNZ or CVAC?
Mainz Biomed NV quarterly revenues are --, which are smaller than CureVac NV quarterly revenues of $63.3M. Mainz Biomed NV's net income of -- is lower than CureVac NV's net income of $319.3M. Notably, Mainz Biomed NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mainz Biomed NV is 0.52x versus 11.69x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MYNZMainz Biomed NV0.52x -- -- -- CVACCureVac NV11.69x 5.89x $63.3M $319.3M
-
Which has Higher Returns MYNZ or EVO?
Evotec SE has a net margin of -- compared to Mainz Biomed NV's net margin of -26.29%. Mainz Biomed NV's return on equity of -2631.22% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital MYNZMainz Biomed NV-- -- $2.8M EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About MYNZ or EVO?
Mainz Biomed NV has a consensus price target of $14.00, signalling upside risk potential of 1150%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 74.02%. Given that Mainz Biomed NV has higher upside potential than Evotec SE, analysts believe Mainz Biomed NV is more attractive than Evotec SE.
Company Buy Ratings Hold Ratings Sell Ratings MYNZMainz Biomed NV0 0 0 EVOEvotec SE1 0 0 -
Is MYNZ or EVO More Risky?
Mainz Biomed NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock MYNZ or EVO?
Mainz Biomed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mainz Biomed NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MYNZ or EVO?
Mainz Biomed NV quarterly revenues are --, which are smaller than Evotec SE quarterly revenues of $191.5M. Mainz Biomed NV's net income of -- is lower than Evotec SE's net income of -$50.3M. Notably, Mainz Biomed NV's price-to-earnings ratio is -- while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mainz Biomed NV is 0.52x versus 1.34x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MYNZMainz Biomed NV0.52x -- -- -- EVOEvotec SE1.34x -- $191.5M -$50.3M
-
Which has Higher Returns MYNZ or IFRX?
InflaRx NV has a net margin of -- compared to Mainz Biomed NV's net margin of -51538.49%. Mainz Biomed NV's return on equity of -2631.22% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital MYNZMainz Biomed NV-- -- $2.8M IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About MYNZ or IFRX?
Mainz Biomed NV has a consensus price target of $14.00, signalling upside risk potential of 1150%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 941.09%. Given that Mainz Biomed NV has higher upside potential than InflaRx NV, analysts believe Mainz Biomed NV is more attractive than InflaRx NV.
Company Buy Ratings Hold Ratings Sell Ratings MYNZMainz Biomed NV0 0 0 IFRXInflaRx NV5 2 0 -
Is MYNZ or IFRX More Risky?
Mainz Biomed NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock MYNZ or IFRX?
Mainz Biomed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mainz Biomed NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MYNZ or IFRX?
Mainz Biomed NV quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of $27.8K. Mainz Biomed NV's net income of -- is lower than InflaRx NV's net income of -$14.3M. Notably, Mainz Biomed NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mainz Biomed NV is 0.52x versus 333.70x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MYNZMainz Biomed NV0.52x -- -- -- IFRXInflaRx NV333.70x -- $27.8K -$14.3M
-
Which has Higher Returns MYNZ or IMTX?
Immatics NV has a net margin of -- compared to Mainz Biomed NV's net margin of -974.45%. Mainz Biomed NV's return on equity of -2631.22% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital MYNZMainz Biomed NV-- -- $2.8M IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About MYNZ or IMTX?
Mainz Biomed NV has a consensus price target of $14.00, signalling upside risk potential of 1150%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 83.46%. Given that Mainz Biomed NV has higher upside potential than Immatics NV, analysts believe Mainz Biomed NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings MYNZMainz Biomed NV0 0 0 IMTXImmatics NV9 0 0 -
Is MYNZ or IMTX More Risky?
Mainz Biomed NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock MYNZ or IMTX?
Mainz Biomed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mainz Biomed NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MYNZ or IMTX?
Mainz Biomed NV quarterly revenues are --, which are smaller than Immatics NV quarterly revenues of $6.1M. Mainz Biomed NV's net income of -- is lower than Immatics NV's net income of -$59.1M. Notably, Mainz Biomed NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mainz Biomed NV is 0.52x versus 13.65x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MYNZMainz Biomed NV0.52x -- -- -- IMTXImmatics NV13.65x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
